Advisory Committees

International Advisory Panel

The International Advisory Panel (IAP) plays a critical advisory role as ACE (i) conducts health technology assessment (HTA) on treatments and technologies, and (ii) strengthens its guidance development methodology and builds its evidence implementation efforts to support clinicians in practising evidence-based medicine, to achieve cost-effective and appropriate healthcare in Singapore. The Panel will also offer a global perspective, which will help us keep abreast of relevant developments and initiatives internationally. IAP members are appointed for a 2-year term starting from 1 Mar 2021 to 28 Feb 2023.

The IAP's terms of reference are to advise ACE on the following areas:

  1. Critique, recommend improvements and advise on ACE’s workplan and initiatives (e.g. drug and medical technology evaluation methods and processes, manufacturer submission’s methods and process manual, guidance development methods and processes) to keep abreast with international best practices;
  2. Provide insights on emerging trends and developments in HTA, and/or guidance development and evidence implementation;
  3. Share approaches to guide Singapore’s implementation efforts to build capabilities in HTA, guidance development and execution of evidence-based practice; and conduct training for ACE staff in these areas; and
  4. Connect ACE to international networks in the area of HTA, guidance development and/or evidence implementation.


Current IAP Members

Meindert Boysen (since Mar 2019)

Deputy Chief Executive and Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), United Kingdom

Board of Directors, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) from 2017 to 2020


Prof Terry Campbell (since Mar 2021)

Emeritus Professor of Medicine, University of New South Wales (UNSW Sydney), Australia

Chair, Prostheses List Advisory Committee (PLAC), Commonwealth of Australia

Director of Research, St Vincent’s Hospital

Sarah Fitt (since Mar 2021)

Chief Executive, Pharmaceutical Management Agency (PHARMAC), New Zealand

Prof Mark Jit (since Aug 2019)

Professor of Vaccine Epidemiology, Department of Infectious Disease Epidemiology, Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, United Kingdom

Visiting Professor, School of Public Health, University of Hong Kong

Dr Nicholas Latimer (since Mar 2021)

Reader in Health Economics, School of Health & Related Research, The University of Sheffield, United Kingdom

Member, National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee B

Member, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Health Science Policy Council

Suzanne McGurn (since Mar 2021)

President and Chief Executive Officer, Canadian Agency for Drugs & Technologies in Health (CADTH), Canada

Member, Health Technology Assessment International (HTAi) Nominating Committee

Prof Tracy Merlin (since Mar 2019)

Professor of Health Technology Assessment, School of Public Health, University of Adelaide, Australia

Director, Adelaide Health Technology Assessment (AHTA)

Chair, Board of the International Network of Agencies for Health Technology Assessment (INAHTA)

Chair, English Editorial Board, International HTA Glossary


Prof Debra Rowett (since Apr 2020)

Discipline Leader Pharmacy: External Relations, UniSA Clinical and Health Sciences, University of South Australia

Director, Drug and Therapeutics Information Service (DATIS), Southern Adelaide Local Health Network

President, Council of Pharmacy Schools: Australia and New Zealand

Member, National Drug Utilisation Sub-Committee of Pharmaceutical Benefits Advisory Committee (PBAC)

Former President, Australian Pharmacy Council

Prof Tim Shaw (since Apr 2020)

Professor of eHealth and Director of Research in Implementation Science and eHealth (RISe), Faculty of Medicine and Health, The University of Sydney, Australia

Director of Research, Digital Health Cooperative Research Centre

Prof Per Olav Vandvik (since Apr 2020)

Chief Executive Officer, MAGIC Evidence Ecosystem Foundation, Norway

Professor of Medicine, Department of Health Management and Health Economics, University of Oslo

Senior Researcher, Norwegian Institute of Public Health, Oslo

Consultant, Department of Medicine, Lovisenberg Diaconal Hospital, Oslo

Prof Allan Wailoo (since Mar 2019)

Professor of Health Economics, School of Health & Related Research, The University of Sheffield, United Kingdom

Director, National Institute for Health & Care Excellence (NICE) Decision Support Unit

Member, NICE Medical Technologies Appraisal Committee (MTAC)

Co-Director, National Institute for Health Research (NIHR) Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions


Prof Robyn Ward (since Mar 2017)

Executive Dean and Pro Vice-Chancellor, Faculty of Medicine and Health, The University of Sydney, Australia

Chair, Commonwealth Medical Services Advisory Committee (MSAC)

Member, Board of the Australian Red Cross Lifeblood

Member, Prosthesis List Advisory Committee (PLAC), Commonwealth of Australia

Member, Genomics Health Futures Mission Expert Advisory Committee, Commonwealth of Australia

Honorary Medical Officer (Oncology), Westmead Hospital, Sydney

Member, RAND Australia Advisory Board

Prof Andrew Wilson (since Mar 2019)

Director, Menzies Centre for Health Policy, School of Public Health, The University of Sydney, Australia

Chair, Pharmaceutical Benefits Advisory Committee (PBAC)

Chair, PICO Advisory Sub-Committee of the Commonwealth Medical Services Advisory Committee (MSAC)

 

Former IAP members

Prof Jonathan Craig 

Member from Mar 2017  - Feb 2021

Vice President & Executive Dean, College of Medicine and Public Health, Flinders University, Australia 

Prof Ron Goeree

Member from Mar 2017 - Feb 2019

Professor Emeritus, McMaster University, Canada

Prof Carole Longson

Member from Mar 2017 - Feb 2019

Former Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), United Kingdom

Dr Brian O’Rourke

Member from Mar 2019 - Feb 2021

Former President and Chief Executive Officer, Canadian Agency for Drugs & Technologies in Health (CADTH), Canada

Prof Paul Scuffham

Member from Mar 2017 - Feb 2019

Director, Centre for Applied Health Economics, Griffith University, Australia

Prof Mark Sculpher

Member from Mar 2017 - Feb 2019

Professor, Centre for Health Economics, University of York, United Kingdom

Prof Ken Stein

Member from Mar 2019 - Feb 2021

Professor of Public Health, College of Medicine and Health, University of Exeter, United Kingdom



ACE Council

The ACE Council was formed as an advisory body to steer the Agency’s development to drive appropriate healthcare in Singapore. Led by an eminent senior clinician, the Council comprises well-respected senior medical specialists and professionals across a range of disciplines.

The combined expertise and experience of Council members in medicine, research and academia, health economics, legal, social policy and government policy, present a holistic perspective to guide the Agency's development.

The Council's terms of reference:

  1. To advise the Ministry on the development of initiatives to promote the use of evidence-based, safe and cost-effective medicines in public hospitals and institutions (PHIs).
  2. To develop strategies to harmonise formulary drugs across PHIs where appropriate and to facilitate timely listing of subsidised drugs.
  3. To advocate appropriate use of medicines by:
    • promoting the use of generic alternatives (including biosimilars) of medicines, where available;
    • working collaboratively with stakeholders to influence appropriate use of medicines in the PHIs (including compliance with ACE Guidance, where available);
    • facilitating the sharing of national drug utilisation data to provide PHIs with appropriate benchmark for reviewing each PHI’s practices.

Professor Chee Yam Cheng (since May 2016)

(Chairman)
Senior Advisor, National Healthcare Group

Dr Daphne Khoo (since May 2016)

(Ex Officio)
Executive Director, Agency for Care Effectiveness

Mr Augustin Lee (since May 2016)

Chief Executive Officer, CPF Board  

Professor Teo Eng Kiong (since Jun 2020)

Master, Academy of Medicine, Singapore
Chief Executive Officer, Sengkang General Hospital
Deputy Group Chairman Medical Board (Regional Hospital Network), Singapore Health Services Pte Ltd
Senior Consultant, Gastroenterology & Hepatology, Department of General Medicine, Sengkang General Hospital

Associate Professor Toh Han Chong (since
Aug 2019)

Deputy Medical Director (Strategic Partnerships) and Senior Consultant, National Cancer Centre Singapore

Assistant Professor Jean Liu (since Aug 2019)

Assistant Professor, Division of Social Sciences (Psychology), Yale-NUS College

Associate Professor Lita Chew (since Aug 2019)

Head of Pharmacy Department, National Cancer Centre Singapore 

Ms Margaret Lee (since Aug 2019)

Chief Nurse, Alexandra Hospital

Ms Olivia Khoo (since Aug 2019)

Head of Department of Medical Social Services, Singapore General Hospital 

Ms Tan-Huang Shuo Mei (since Aug 2019)

Senior Director, Special Projects, SingHealth

Associate Professor Suresh Sahadevan (since Aug 2019)

Senior Consultant, Departments of General Medicine and Geriatric Medicine, Tan Tock Seng Hospital 

Ms K Thanaletchimi (since Aug 2019)

Vice President, NTUC Central Committee
President, Healthcare Services Employees’ Union (HSEU)

Dr Wong Tien Hua (since May 2016)

Director, Mutual Healthcare Pte Ltd, Singapore
Past President - Singapore Medical Association
 

Adjunct Associate Professor Tan Tze Lee (since Aug 2019)

President, College of Family Physicians Singapore
Senior Partner, The Edinburgh Clinic
Adjunct Associate Professor in Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore

Ms Tan Yee Peng (since May 2016)

Chartered Accountant